Navigation Links
Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, announced results from two pre-clinical studies that support the role of SPARC (secreted protein acidic and rich in cysteine) expression in cancer and Abraxis' nanoparticle albumin-bound (nab(TM)) tumor-targeting technology at the 98th American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2007 in Los Angeles.

"Both pre-clinical studies evaluating the role of SPARC expression provide strong evidence in support of the mechanism of action for our nab-technology therapeutic candidates," said Neil P. Desai, Ph.D., vice president of research and development at Abraxis BioScience. "By leveraging the natural properties of albumin, nab-technology allows for the transport and delivery of higher concentrations of anticancer agent directly to the tumor without the use of toxic solvents. Both pre-clinical and clinical studies have shown that this may lead to an increase in the drug's antitumor effect without increasing side effects."

The first of two pre-clinical studies demonstrated that SPARC is an albumin-binding protein and that the level of the SPARC expression could be correlated with the response of tumors to nab-paclitaxel. This provides concrete support for the earlier hypothesis that higher levels of SPARC protein may lead to enhanced antitumor effect of nab-paclitaxel, which is marketed in the United States under the brand name ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particle for injection (albumin bound). (Abstract #3480; SPARC Overexpression Enhances Sensitivity to nab-paclitaxel In Vivo).

The second of the two pre-clinical studies identified a novel spliced variant of SPARC gene that differed from known human SPARC mRNA sequence by a single amino acid residue. Although the role of this form of SPARC is still under
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:2/27/2015)... An aggressive campaign to reduce the unnecessary ... infection with a dangerous drug-resistant bacteria at The Valley ... or C.diff, is a bacterium that can cause symptoms ... A recent article in the New England Journal of ... the United States " asserts that "C. ...
(Date:2/27/2015)... ON , Feb. 27, 2015 /CNW/ - Covalon Technologies ... medical technologies company, today announced financial results for its ... For the three months ended December 31, 2014, revenue ... the quarter was $229,820 or $0.02 per share.  ... , said "I am very pleased with the significant ...
(Date:2/27/2015)... 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... it acquired Bionik Laboratories, Inc., a Toronto ... to qualified accredited investors of units consisting of its ... approximately $6.2 million. Shares of the Company,s common stock ... under the symbol "DWTPD" until FINRA,s approval of the ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... 6, 2011 The U.S. Food and Drug Administration ... (metastatic) medullary thyroid cancer who are ineligible for surgery ... symptoms. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the thyroid gland, which is located in the neck. ...
... April 6, 2011 Quest Diagnostics Incorporated (NYSE: ... testing, information and services, today announced that the Simplexa™ ... with a bronze award for best new science and ... ceremony last night in New York City. Focus Diagnostics, ...
Cached Medicine Technology:FDA Approves New Treatment for Rare Form of Thyroid Cancer 2FDA Approves New Treatment for Rare Form of Thyroid Cancer 3Quest Diagnostics Honored for Diagnostic Innovation at 2011 Edison Awards 2Quest Diagnostics Honored for Diagnostic Innovation at 2011 Edison Awards 3
(Date:3/1/2015)... Ticket Down is a reputable source for ... Soldier Field. Deadheads have been anxiously anticipating this blockbuster ... Dead was formed 50 years ago back in the 60s ... until the untimely death of Jerry Garcia in 1995. ... blues, reggae, rock, bluegrass, folk, space rock and country to ...
(Date:3/1/2015)... Aliso Viejo, California (PRWEB) March 01, 2015 ... have announced a new transition pack for ... users to add accordion style transitions to any FCPX ... Studios. “We’ve given our users the tools needed to ... FCPX media.” , The user gets many different controls ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 In a ... Fletcher of Game Change Athlete Development ... Leinert about the benefits of athlete development and player ... of the unique challenges that athletes face and how ... future success. , Fletcher became involved in athlete development ...
(Date:2/28/2015)... March—also known as National Brain Injury ... and others that suspected head injuries, especially concussions, ... , Concussions are a form of traumatic brain ... There are 1.6-3.8 million sports-related concussions per year. ... is a brain injury. Many athletes suffer knee ...
(Date:2/28/2015)... For those people who are unable ... Mesothelioma Applied Research Foundation (Meso Foundation) will broadcast ... starting at 9:30 AM. , The live broadcast is ... can be accessed through any browser on a computer ... Symposium is a unique event that covers important treatment ...
Breaking Medicine News(10 mins):Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2
... -- The cost of health care is a hot-button issue ... that health insurance premiums for individuals vary widely around the ... the United States in 2010 was $215, researchers from the ... vary by up to $300 from state to state. ...
... Hamilton, ON (August 17, 2011) Active children ... effective way of countering dehydration than a sports drink ... That,s particularly important during hot summer weather, says Brian ... Medicine Program at McMaster and principal investigator of the ...
... Patients with clinically diagnosed superficial vein thrombosis (SVT), a blood ... resolves on its own without treatment, are four to six ... often life-threatening condition, according to study results published ... the American Society of Hematology (ASH). Recent ...
... latex allergy in health care workers have demonstrated the ... is by stopping the use of powdered latex gloves. ... latex allergy to powdered latex glove use but were ... workers. Reducing the use of powdered gloves reduced the ...
... Minn. Mayo Clinic has received investigational ... the Food and Drug Administration ( http://www.fda.gov/ ... mobilize the body,s defense mechanisms to destroy ... first aimed at preventing cancer recurrence. The ...
... (HealthDay News) -- Many drugs already approved to combat certain ... other seemingly unrelated health problems, a new study indicates. ... computers to pair drugs with all illnesses for which they ... for drug repositioning -- or the use of existing drugs ...
Cached Medicine News:Health News:Cost of Health Coverage in U.S. May Depend on Where You Live 2Health News:Common vein condition increases risk for developing life-threating blood clots 2Health News:Using powder-free latex gloves reduces latex allergy rate in health care workers 2Health News:Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines 2Health News:New Uses Found for Old Drugs 2
... Guidant Contak Renewal 3 cardiac ... tachyarrhythmia therapy and cardiac resynchronization ... ventricular (RV) and left ventricular ... to reduce irregular ventricular intervals ...
... Contak Renewal 3 cardiac resynchronization ... therapy and cardiac resynchronization therapy. ... (RV) and left ventricular (LV) ... reduce irregular ventricular intervals during ...
... Contak Renewal 3 cardiac resynchronization ... therapy and cardiac resynchronization therapy. ... (RV) and left ventricular (LV) ... reduce irregular ventricular intervals during ...
... brain biopsy needle guide housing. MRI-compatible. ... mount. Placed through a standard 1.0 ... via autoclave Guide sphere assembly with a ... needles with barium sleeves. Sterile; single-use only ...
Medicine Products: